
Boston Scientific Corp. (NYSE:BSX) set out to compare its new Promus Element drug-eluting stent system with Abbott’s (ABT) Xience Prime.
The BSX-funded study will evaluate coronary revascularization outcomes in a 2,980-patient sample across 50 sites in France, Germany, Italy, Spain and the U.K.
Former iterations of the Promus line were private-label versions of Abbott’s Xience V drug-eluting stents, but the Natick, Mass.-based stent pioneer’s deal to rebrand its rival’s devices ended last year.
BSX won CE Mark approval for the Promus Element, its third-generation DES model, in October.